Is CagriSema better than Ozempic or Wegovy?

CagriSema combines semaglutide, the active ingredient in Ozempic and Wegovy, with cagrilintide, a new compound that mimics the natural hormone amylin. Amylin helps regulate your blood sugar, slows down digestion, and reduces appetite. In one trial, those with obesity or overweight who adhered to CagriSema treatment had a greater weight loss of 22.7% after 68 weeks, compared to a 11.8% loss with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg, and 2.3% with a placebo. While good, these results were less the 25% weight loss that was expected with CagriSema.

In another trial in patients with obesity or overweight and type 2 diabetes (T2D), the results were also below expectations. The patients taking CagriSema saw a 15.7% weight loss over 68 weeks, compared with a 3.1% loss in those taking a placebo. A weight loss of ≥5% after 68 weeks was achieved by 89.7% of patients on CagriSema, compared to 30.3% for placebo.
So, while CagriSema may be better for some people when compared to Ozempic or Wegovy, it does not appear to be the gamechanger Novo Nordisk thought it would be.

Source

• CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial. HCP Live. Accessed June 9, 2025.